Clinical Trials Logo

Arthritis clinical trials

View clinical trials related to Arthritis.

Filter by:

NCT ID: NCT03215407 Not yet recruiting - Clinical trials for Rheumatoid Arthritis of Knee

The Comparative Study of Intra-articular Injection of Tocilizumab and Compound Betamethasone

Start date: August 1, 2017
Phase: Phase 4
Study type: Interventional

Aim: Comparing the efficacy and safety of intra-articular injection of tocilizumab and compound betamethasone. Study design: A randomized, single-blind, parallel controlled and one center trial design. Sample size: 60 cases. Study content: Patients who meet inclusive criteria will be randomly divided into tocilizumab group and compound betamethasone group. In the baseline period, the investigators will collect patients' general information, disease information, disease activity score, laboratory results and images of articular ultrasound. After 4 weeks of injection, patients will be asked to come back, and their disease information, disease activity score, laboratory results as well as images of articular ultrasound will be collected. Finally, these data will be sorted and analyzed. Hypothesis: The efficacy and safety of intra-articular injection of tocilizumab is better than that of compound betamethasone.

NCT ID: NCT03214263 Recruiting - Psoriatic Arthritis Clinical Trials

Identification of New Biomarkers to Promote Personalized Treatment of Patients With Inflammatory Rheumatic Diseases

Start date: May 2015
Phase:
Study type: Observational [Patient Registry]

Introduction: The medical treatment of inflammatory rheumatic diseases has improved dramatically during the last decades primarily due to the introduction of biological disease modifying anti-rheumatic drugs (bDMARDs). However, bDMARD treatment failure occurs in 30-40% of patients due to lack of effectiveness or side effects. The tools to predict treatment outcomes in the individual patient are currently limited. The objective of the present study is to identify diagnostic, prognostic and predictive biomarkers, which can be used to 1) diagnose inflammatory rheumatic diseases early in the disease course with high specificity and sensitivity, 2) improve prognostication or 3) predict treatment effectiveness and tolerability for the individual patient. Methods and analysis: Observational and translational open cohort study with prospective collection of clinical data and biological materials in patients with inflammatory rheumatic diseases treated in routine care. Patients contribute one cross-sectional blood sample (i.e. whole blood, serum, EDTA-plasma and -buffy coat, and blood in PAXgene RNA tubes) and/or are enrolled for longitudinal follow-up upon start of new DMARD (blood sampling after 0/3/6/12/24/36/48/60 months' treatment). Demographics, disease characteristics, comorbidities and lifestyle factors are registered at inclusion; DMARD treatment and outcomes are collected repeatedly during follow-up. Currently (June 2017) >5,000 samples from ≈3,000 patients have been collected. Data will be analysed using appropriate statistical analyses. Ethics and dissemination: The protocol is approved by the Danish Ethics Committee and The Danish Data Protection Agency. All participants give written informed consent. Biomarkers will be evaluated and published according to REMARK, STROBE and STARD guidelines. Results will be published in peer-reviewed medical journals and presented at international conferences.

NCT ID: NCT03194204 Completed - Clinical trials for Rheumatoid Arthritis

Re-evaluation of Some Old Rheumatoid Arthritis Therapy: A Randomized Controlled Trial

Start date: October 1, 2019
Phase: N/A
Study type: Interventional

Rheumatoid Arthritis (RA) is a chronic inflammatory disease characterized by joint swelling, joint tenderness and destruction of synovial joints, leading to severe disability and premature mortality.

NCT ID: NCT03193957 Completed - Clinical trials for Rheumatoid Arthritis

An Multicentre Clinical Study to Evaluate the Usability and Safety of the Autoinjector and Pre-filled Syringe of SB4 in Subjects With Rheumatoid Arthritis

Start date: May 15, 2017
Phase: Phase 2
Study type: Interventional

A study comparing the usability of the Autoinjector and Pre-filled Syringe of SB4 in Subjects with Rheumatoid Arthritis.

NCT ID: NCT03192267 Recruiting - Clinical trials for Rheumatoid Arthritis

Early Rheumatoid Arthritis Lung Disease Study

Start date: February 1, 2017
Phase:
Study type: Observational [Patient Registry]

The primary goal of this study is to investigate lung disease, through pulmonary function and high resolution chest CT, in newly diagnosed rheumatoid arthritis (RA) patients. Extra-articular disease occurs in approximately 50% of RA patients, with the lung being a common site of involvement. Investigators goal is to understand the prevalence of lung disease in early RA patients and to better characterize it through questionnaires, imaging, and serum studies. Additionally, the goal is to find novel biomarkers to predict lung disease in RA patients.

NCT ID: NCT03191539 Not yet recruiting - Clinical trials for Arthritis; Psoriasis (Etiology)

Assessment of the Clinical and Ultrasound Response to Apremilast by Clinical Evaluation and by a Joint-periarticular-nail Ultrasound Index in Patients With Active Psoriatic Arthritis

APREMILAST
Start date: November 2, 2017
Phase: Phase 3
Study type: Interventional

This study aims to evaluate more objectively, through an imaging technique such as ultrasound, changes in joints and entheses of patients with active psoriatic arthritis (PAs) who will start treatment with Apremilast after the failure of other therapies such as synthetic DMARD (metrotrexato , Leflunomide ...). The hypothesis of the study is that the technique of ultrasound can demonstrate the efficacy of Apremilast in the treatment of patients with active PAs

NCT ID: NCT03190746 Completed - Clinical trials for Rheumatoid Arthritis

Relationship of YWHAH Polymorphisms to Rheumatoid Arthritis Disease Severity

Start date: June 1, 2015
Phase: N/A
Study type: Observational

It is hypothesized that one or several of these 6 single nucleotide polymorphisms (SNPs) (rs2246704, rs2853884, rs3747158, rs4820059, rs7291050, and rs933226) in the YWHAH gene could be related to RA disease severity.

NCT ID: NCT03189303 Completed - Clinical trials for Osteoarthritis; Rheumatoid Arthritis; Post Traumatic Arthritis

Cup Position in THA With Standard Instruments

Start date: September 7, 2017
Phase:
Study type: Observational

Prospective, global, multicenter study to assess cup position in THA. After written informed consent has been obtained, study evaluations will be collected from the pre-op clinic visit, the operative visit (including discharge), and 6 and 12 weeks postoperatively.

NCT ID: NCT03188081 Completed - Clinical trials for Rheumatoid Arthritis

A Study to Investigate the Effectiveness of an Education Support Program on Medication Adherence in Italian Real Life Rheumatoid Arthritis (RA) Patients Treated With Subcutaneous (SC) Abatacept

TIGHT
Start date: August 2, 2017
Phase:
Study type: Observational

The primary objective of this study is to investigate whether an Educational Supported Program (ESP), including tight control procedures implemented through patient home care, has positive impact in terms of better adherence to the therapy with abatacept SC at 12 months after treatment start (1st injection). In the scope of this objective the adherence is measured by the Medication Adherence Questionnaire (MAQ).

NCT ID: NCT03187444 Active, not recruiting - Clinical trials for Cardiovascular Diseases

Cardiovascular Risk and Chronic Inflammatory Rheumatism

RCVRIC
Start date: April 24, 2015
Phase: N/A
Study type: Interventional

Chronic inflammatory rheumatism and inflammation can increase the risk of cardiovascular problems. Indeed, these diseases can increase the risk of myocardial infarction. The objective of this project is a better understanding and preventing the risk of cardiovascular problems in chronic inflammatory rheumatism through the study on the long-term flexibility of the arteries, blood markers of cardiovascular risk and muscle mass.